Authors' Response

The views expressed in this letter are the authors' and do not reflect the views of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. 2002. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of the American Medical Association 288 (23): 2981–2997.

Chobanian A.V. Bakris G.L. Black H.R. Cushman W.C. Green L.A. Izzo J.L. Jr. Jones D.W. Materson B.J. Oparil S. Wright J.T. Jr. Roccella E.J. , 2003. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (6): 1206–1252.

Garattini S. Bertelé V. , 2003a. Efficacy, Safety and Cost of New Drugs Acting on the Central Nervous System. European Journal of Clinical Pharmacology 59 (1): 79–84.

Garattini S. Bertelé V. , 2003b. Efficacy, Safety and Cost of New Cardiovascular Drugs: A Survey. European Journal of Clinical Pharmacology 59 (8–9): 701–706.

Lichtenberg F. 2002. Benefits and Costs of Newer Drugs: An Update. NBER Working Paper no. 8996. Cambridge, Mass.: National Bureau of Economic Research (NBER).

Lieberman J.A. Stroup T.S. McEvoy J.P. Swartz M.S. Rosenheck R.A. Perkins D.O. Keefe R.S. Davis S.M. Davis C.E. Lebowitz B.D. Severe J. Hsiao J.K. , Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. 2005. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine 353 (12): 1209–1223.

Miller G.E. Moeller J.F. Stafford R.S. , 2005/2006. New Cardiovascular Drugs: Patterns of Use and Association with Non-Drug Health Expenditures. Inquiry 42 (4): 397–412.

Mintzes B. Lexchin J. , 2005. Do Higher Drug Costs Lead to Better Health? Canadian Journal of Clinical Pharmacology; 12 (1): e22–27.

National Asthma Education and Prevention Program Expert Panel. 2002. National Asthma Education and Prevention Program Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics—2002. Journal of Allergy and Clinical Immunology 110 (5 pt 2): S141–219.

Shireman T.I. Rigler S.K. Jachna C.M. Griebling T.L. Eng M.L. , 2005. The Cost Effect of Newer Medication Adoption in an Older Medicaid Cohort. Journal of the American Geriatrics Society 53 (8): 1366–1373.

Vermeulen L.C. 2002. Value on the Margin? American Journal of Health-System Pharmacy 59 (6): 1.